ABSTRACT
INTRODUCTION
Lipid bodies are non-membrane bound, lipid-rich cytoplasmic inclusions that form in diverse cell types.1 While lipid inclusions exist in steroid-producing cells and pre-adipocytes and are storage sites of esterified cholesterol,2 in most cells little is known about the origins, composition or functions of lipid bodies. In limited numbers, lipid bodies are normal constituents of many cells, including neutrophils (PMN), eosinophils, mast cells, macrophages, endothelial cells and fibrob asts.' Numbers of lipid bodies typically increase when cells are participating in varied inflammatory or pathologic processes.1, 3 7 In addition, lipid bodies are numerous in sites active in eicosanoid formation, such as the amnion epithelium at parturition.8 Attention to lipid bodies is engendered by the roles that these cytoplasmic organelles play in arachidonate metabolism by eosinophils and other leukocytes involved in inflammation. Our findings indicate that lipid bodies function as intracellular domains that are both depots of esterified arachidonate and sites at which regulated enzymatic events relevant to arachidonate metabolism can occur. Lipid bodies constitute distinct structures whose formation is specifically inducible early (within 1h), whose increased numbers correlate with the 'priming' responses of leukocytes to form enhanced quantities of both cyclooxygenase (COX)-and lipoxygenase (LO)-derived eicosanoids and whose inhibition of formation correlates with reduced synthesis of these eicosanoids. Inhibition of lipid body formation represents a new and feasible pharmacologic target to block the formation of eicosanoid mediators of inflammation.
We will review arachidonate metabolism pertinent to eicosanoid formation and current knowledge of lipid bodies, including their occurrence in vivo, their formation in vitro and their constituents, and then consider the roles lipid bodies may play in the heightened elaboration of eicosanoids by cells involved in inflammation.
ARACHIDONIC ACID METABOLISM
Oxidative metabolism of arachidonate occurs by one of three pathways involving COX, LO or cytochrome P450 monooxygenase enzymes.9,10 Products of these pathways, termed eicosanoids, have diverse biological activities.9,11 Arachidonate and eicosanoids function as autocrine signals.12 Eicosanoids are also potent paracrine mediators of inflammation. 13 The COX pathway, present in cells either as constitutive COX-1 and/or as an inducible COX-2 enzyme, forms prostaglandins (PG) and thromboxanes.14-16 The 5-LO pathway, present in PMN, eosinophils, monocytes, mast cells and macrophages, forms 5-hydroxyeicosatetraenoic acid (5-HETE) and leukotrienes (LT).10 15-Lipoxygenase, present in some leukocytes, especially eosinophils, is interleukin (IL)-4-inducible in other cells and active in inflammatory sites, including airways.10 The formation of eicosanoids, not stored preformed within cells, is tightly regulated and enhanced formation of eicosanoids, necessary for their paracrine activities, occurs in response to activating stimuli.10 Eicosanoid formation is rate-limited in part by the availability of free arachidonate. Within cells, arachidonate is not free but is incorporated within glycerolipids,17 especially phospholipids. 18 The availability of free arachidonate is governed by enzymatic reactions that cause its acylation19 and its release from phospholipids. Little is known about arachidonate uptake into phospholipids and focus on initiation of arachidonate oxidative metabolism is directed towards enzymatic reactions that release it from phospholipids. An initial regulatory event involves activation of arachidonatereleasing phospholipases (PL). Increases in intracellular Ca2+ and phosphorylation activate some, but not all, PL. The importance of some PL and their ability to preferentially release eicosanoid-precursor arachidonate remain unsettled.20 Specific cytosolic PLA2 enzymes that are arachidonyl phospholipid-specific have been identified. 21 Platelet-activating factor-induced lipid body formation was inhibited by lipoxygenase inhibitors, including the FLAP inhibitor MK886,33 the anti-5-LO agent zileuton, diethylcarbamazine (DEC) and nordihydroguiaretic acid (NDGA). Platelet-activating factor-induced lipid body formation was not inhibited by COX inhibitors. To confirm the 5-LO dependence of PAF-induced signaling for lipid body formation, we evaluated PAF induction of lipid bodies in PMN and macrophages from normal and 5-LO knock-out mice.49 Interestingly, 5-LO knock-out mice are known to be resistant to the lethal effects of PAF49,50 In PMN and peritoneal macrophages from normal mice, PAF stimulated lipid body formation; however, in cells from 5-LO-deficient mice, PAF failed to stimulate lipid body formation.39 Thus, a requisite role for 5-LO in PAFinitiated induction of lipid body formation was established both with pharmacologic inhibitors of 5-LO activity and with genetically deficient 5-LO leukocytes.
As 5-LO activity was obligately required to mediate PAF-induced signaling for lipid body formation, we evaluated the enzymatic products of 5-LO that act to stimulate lipid body formation.39 Notably, LTB4 was not active. In addition, an LTB4 receptor antagonist (CR 105 696) did not block PAF-induced lipid body formation, confirming the lack of a role for both exogenous and endogenous LTB4 in PAF-initiated lipid body formation. Instead, 5 (S)-HETE was the 5-LO product active in lipid body induction. 5 (S)-Hydroxyeicosatetraenoic acid induced dose-and time-dependent increases in PMN lipid body formation. 5 (S)-Hydroxyeicosatetraenoic acid was active at lower concentrations (10-9 to 10-7mol/L) than PAF and was more active than 5 (R)-HETE and 5-oxo-ETE.39 Moreover, 5 (S)-HETE induced lipid bodies in cells from 5-LO knock-out mice, cells unable to generate their own PAF-induced 5-HETE due to the absence of 5-LO. 39 As with PAF itself, 5 (S)-HETE-induced lipid body formation was inhibited by pertussis toxin. 5-Hydroxyeicosatetraenoic acid has previously been shown to stimulate PMN by a stereospecific, G-protein-linked, perfussis toxin-inhibitable mechanism, suggestive of a specific 5-HETE receptor.51 Thus, PAF-induced lipid body formation proceeds through a 5-LO-dependent signaling cascade that generates 5 (S)-HETE as an intracrine activator. These findings document one specific receptorinitiated pathway involved in the rapid induction of lipid body formation. The activities of fatty acids as lipid body inducers were structurally restricted.44 Fully saturated fatty acids (e. g.
palmitate, myristate) and methyl esters of oleate and arachidonate were inactive.44 Unsaturated fatty acids with cis geometries in their double bonds were considerably more active than those with trans double bonds and activity as inducers of lipid body formation increased with an increasing number of double bonds in C18 and C20 fatty acids. Lipid body inducing activities of cis-fatty acids were not due to fatty acid-derived or-elicited oxidants. 44 The stereochemically restricted potency of fatty acids as lipid body inducers suggested that a specific mechanism was involved.
NSAID dependence of cis-fatty acid-induced lipid body formation
To determine whether eicosanoids function in lipid body formation elicited by cis-fatty acids, potential COX and LO inhibitors were evaluated as inhibitors of cis-fatty acid-induced lipid body formation. Aspirin inhibited lipid body formation induced by cis-fatty acids in both human PMN and in eosinophils, as did the structurally unrelated NSAID indomethacin and piroxicam. Moreover, sodium salicylate (which does not substantially inhibit COX) was as potent as ASA in inhibiting lipid body formation elicited by cis-fatty acids, suggesting that NSAID inhibition of lipid body formation was independent of COX inhibition. Neither ASA, indomethacin nor sodium salicylate inhibited
[14C]-AA uptake by human PMN stimulated by AA, indicating that these agents were not acting by diminishing fatty acid uptake. The lipoxygenase inhibitors zileuton, NDGA, DEC and MK886, did not inhibit cis-fatty acidinduced lipid body formation, in contrast to their inhibition of PAF-induced lipid body formation. Thus, ASA and varied NSAID, but not LO inhibitors, inhibited cis-fatty acid-induced lipid body formation. 38 We next evaluated whether the inhibitory actions of ASA and NSAID were attributable to COX inhibition and several findings demonstrated that inhibition of cis-fatty acid induced lipid body formation by these agents was not COX-dependent.38 First, the inhibition of lipid body induction by sodium salicyclate, an anti-inflammatory agent of uncertain action as it is unable to acetylate and inhibit COX enzymes, suggested a lack of dependence on COX inhibition. Second, cis-fatty acids, AA and OA all induced lipid body formation in macrophages from COX-1 and COX-2 genetically deficient mice identically as in macrophages from wild-type mice. Third, NSAID (indomethacin, sodium salicylate and NS-398) inhibited lipid body formation stimulated by both OA and AA in macrophages from COX-1 and COX-2 mice. Interestingly, NS-398, a nominally specific COX-2 inhibitor,52 blocked lipid body formation in macrophages from wildtype and COX-1-and even COX-2-deficient mice, indicating that the anti-inflammatory actions of NS-398 are not restricted to COX-2 inhibition, but may also be based on inhibiting lipid body formation.
Thus, ASA and NSAID, via a COX-independent mechanism, inhibit cis-fatty acid-induced lipid body formation and this finding, together with related data on the suppression of eicosanoid formation presented later, expands the range of anti-inflammatory actions of these agents.38 With similar approaches, we can localize other arachidonate-releasing and LT-synthesizing enzymes to leukocyte lipid bodies (PF Weller et al., unpubl. obs., 1997). These novel findings support the capacity of lipid bodies to serve as sites for local eicosanoid formation. The co-compartmentalization of arachidonyl-phospholipids, cPLA2, its activating kinases and eicosanoidforming enzymes provides in one site an efficient means to regulate arachidonate release and couple it directly with oxidative metabolism to form eicosanoids.
USE OF LIPID BODY DERIVED ARACHIDONATE FOR EICOSANOID SYNTHESIS
We have correlated lipid body induction with enhanced, primed synthesis of eicosanoids. Our hypothesis predicts that induction of lipid bodies will lead to enhanced formation of both COX-and LO-derived eicosanoids. We have extensively tested this prediction. All lipid body inducing stimuli lead to enhanced eicosanoid generation. Moreover, increasing lipid body numbers correlate directly with increasing levels of LO-and COX-derived eicosanoids generated by leukocytes. Human eosinophils or PMN were pre-incubated for 1h with concentrations of distinct stimuli to induce lipid body formation: OA (a cis-fatty acid not an eicosanoid substrate), AA, OAG or PAF. Lipid bodies were enumerated, and replicate leukocytes were challenged with submaximal (0.25-0.5 mol/L) calcium ionophore A23187. Increasing concentrations of each of the four stimuli led to increasing lipid body numbers and, correspondingly, increasing LTC4 production.38,39 The increasing amounts of LTC4 formed paralleled and statistically correlated with numbers of lipid bodies induced with each of the four stimuli.
Analogously, after leukocyte lipid bodies were induced with cis-fatty acids, magnitudes of LTB4 and PGE2 production correlated with PMN lipid body numbers and amounts of LTC4 correlated with eosinophil lipid body numbers.38 Arachidonic acid, as well as OA, dosedependently induced concordant increases in both lipid body numbers and priming for enhanced LTB4, PGE2 and LTC4 production. Increased numbers of AA-and OAinduced lipid bodies in both cell types correlated with the increased quantities of each eicosanoid generated by the primed leukocytes. Notably, stimulation of leukocytes with OA, not itself an eicosanoid precursor fatty acid, led to increments in the production of each eicosanoid that quantitatively paralleled the incremental increases in lipid body numbers (PGE2 r=0.99, P<0.01; LTB4 r=0.99, P<0.01; LTC4 r=0.95, P<0.05). Thus, the capacity of two different leukocyte types to generate greater quantities of COX and LO pathway derived eicosanoids correlated with levels of lipid bodies in these cells. 38 With PAF as a stimulus we have evaluated both the dose and time dependence of lipid body induction and priming for enhanced eicosanoid release in human PMN. 39 The PMN were incubated with increasing concentrations of PAF (10-8 to 10-6mol/L) for 5 min or 1h. After incubation, lipid bodies were enumerated and replicate leukocytes were stimulated with submaximal dose-dependent increases in PMN lipid body numbers after 1h, but not as early as 5min after stimulation. Incubation with PAF for only 5min failed to prime PMN for enhanced LTB4 or PGE2 production. However, after 1h of PAF stimulation, significant dose-dependent priming for enhanced production of both LTB4 and PGE2 was noted. Platelet-activating factor induced 5.5-and 2.8-fold increases in the production of LTB4 and PGE2, respectively, at the highest PAF concentration (10-6 mol/L). Furthermore, there were statistically significant, positive correlations between the PMN content of lipid bodies and priming for enhanced LTB4 (r=0.986, P<0.001) and PGE2 (r=0.971, P<0.001) generation.39 Thus, there were both dose-and timedependent correlations between lipid body formation and enhanced eicosanoid formation, further indicating that lipid bodies contribute to eicosanoid formation. In all of these studies with each stimulus for lipid body induction, the quantities of produced eicosanoids, both COX-and LO-derived, demonstrated statistically significant correlations with the numbers of induced lipid bodies. While this is correlative and not alone definitive proof that lipid bodies are sites of augmented eicosanoid synthesis, these findings are fully supportive of potential roles for lipid bodies in enhanced eicosanoid production.
As the induction of COX-2 by inflammatory stimuli represents one inducible mechanism to augment prostanoid production, we determined which COX was responsible for enhanced PG production by evaluating the effects of COX-1 or COX-2 deficiency on priming.38 Primed COX-2-deficient macrophages were found to be indistinguishable from wild-type cells in both lipid body and PGE2 formation, indicating that COX-2 does not have a role in enhanced PG production. However, primed COX-1-deficient macrophages demonstrated severely diminished levels of PGE2, identifying COX-1 as the enzyme responsible for enhanced PGE2 production induced early in AA-primed macrophages. As the induction of COX-2 expression by stimuli including LPS57 requires up to 48h, our findings with lipid bodies identify lipid body induction as a more rapid and COX-2-independent means to increase production of both COXand LO-derived eicosanoids. We evaluated whether aspirin (ASA) inhibition of lipid body formation would affect cis-fatty acid-induced priming for enhanced production of both COX-and lipoxygenase-derived eicosanoids.38 Aspirin pretreatment inhibited PGE2 production by human PMN and eosinophils in vehicle-and cis-fatty acid-stimulated leukocytes, but this ASA inhibition of prostanoid production may be due solely to ASA inhibition of COX. In contrast, ASA is devoid of direct inhibitory effects on LO in leukocytes and platelets. [64] [65] [66] We have demonstrated that ASA significantly inhibits AA-and OA-induced priming for enhanced production of 5-LO-derived LTB4 by PMN and LTC4 by eosinophils and that sodium salicylate similarly inhibited cis-fatty acid-induced priming for enhanced LTB4 production by PMN. Aspirin was not acting to block pathways of AA mobilization or metabolism activated by calcium ionophore, as aspirin failed to inhibit calcium ionophore-induced LTB4 and LTC4 production in cells not prestimulated with cis-fatty acids and was not inhibiting eicosanoid export (no residual intracellular eicosanoids were detectable). The inhibition by aspirin of priming for enhanced eicosanoid production correlated with its ability to inhibit cis-fatty acid-induced lipid body formation.38 Thus, inhibitors of lipid body induction, whether they be ASA/NSAID blocking OA-or AA-induced lipid body formation or inhibitors of mRNA and protein synthesis, also inhibited the enhanced production of both COXand LO-derived eicosanoids. This provides additional support for the hypothesized roles of lipid bodies as inducible sites active in the enhanced generation of eicosanoid mediators of inflammation. Moreover, the capacity of inhibitors of lipid body induction to block eicosanoid formation identifies a novel target for antiinflammatory drug action. Notably, the suppression by ASA and NSAID of lipid body production and of LT and PG production, by a COX-independent mechanism, expands our understanding of the anti-inflammatory actions of these drugs. Aspirin and NSAID block cis-fatty acid-induced lipid body formation and concomitantly inhibit formation of both COX-and LO-derived eicosanoids.
CONCOMITANT INHIBITION OF LIPID BODY INDUCTION AND EICOSANOID FORMATION

CYCLOHEXIMIDE-ACTINOMYCIN D INHIBITION OF ENHANCED EICOSANOID GENERATION
RELEVANCE OF LIPID BODIES TO EICOSANOID PRODUCTION BY INFLAMMATORY CELLS
If lipid bodies have specific roles in contributing to eicosanoid mediator formation in inflammation, lipid bodies may provide distinct advantages.
As membrane-sparing domains Eicosanoids derive from arachidonyl-phospholipids assumed to reside in membranes, but which membranes and, indeed, whether it is membranes that serve as depots of precursor arachidonate are unknown. In one study, cells lost their capacity to form PGE2 after deprivation of exogenous arachidonate for 24-48h. 67 We have documented a relationship between lipid body formation and primed responsiveness for augmented eicosanoid formation. With each class of lipid body inducer (PAF, OAG, cis-fatty acids, LPS), we have now established that numbers of induced lipid bodies correlate with magnitudes of enhanced COX-and LOderived eicosanoids. Moreover, inhibition of lipid body induction with various inhibitors correlates with suppression of priming for enhanced eicosanoid generation. Aspirin inhibition of OA-induced lipid body formation even suppresses generation of 5-LO (not itself ASAinhibitable)-derived LT. Thus, prior induction of lipid body formation is associated with the capacity for primed generation of eicosanoids, and inhibition of lipid body formation is associated with diminished capacity to form both COX-and LO-derived eicosanoids.
As an inducible early mechanism to enhance inflammation In contrast to normal leukocytes studied ex vivo, in vivo it is cells associated with inflammation, those likely to contain many lipid bodies, that, are producing quantities of eicosanoids.7 For instance, PMN from casein-elicited rodent peritoneal exudates produced more LTB4 than did normal PMN72 and activated 'hypodense' human eosinophils (which contain many lipid bodies3) form more LTC4 than normal eosinophils.73 In leukocytes and other cells associated with inflammation, the mobilization of arachidonate for eicosanoid formation may differ from that studied in more readily obtainable normal blood leukocytes. 7 The capacity of leukocytes to rapidly form lipid bodies in association with inflammatory processes provides a means by which these cells can rapidly develop specialized intracellular domains that augment their capability to generate eicosanoid mediators of inflammation. In comparison with the induction of COX-2, which occurs over 2-48h and augments only PG production, induction of lipid body formation develops within 1h and is associated with enhanced formation of both PG and LT. Thus, the induction of lipid body formation is a distinct, early developing response that constitutes a means to augment the generation of diverse eicosanoid mediators of inflammation.
As a site for cytokine actions 
